EMBECTA CORP
EMBCNASDAQTrading Snapshot
- Day Range
- $5.69 – $5.87
- 52-Week Range
- $2.77 – $14.91
- Volume
- $2.71B
- Avg Volume
- $3.02B
- Shares Outstanding
- 59.3M
- Next Earnings
- Dec 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.08B
- Last Q Revenue
- $272M
- P/E Ratio
- 4.0
- P/S Ratio
- 0.3x
- EPS (TTM)
- $1.50
- Dividend Yield
- 5.40%
- Dilution (1yr)
- +0.5%
Why Investors Own EMBC
- ✓High-growth profile — revenue up -2.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
EMBECTA CORP
EMBC
StockOtter · stockotter.spaceAbout EMBECTA CORP
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and off
embecta to Participate in Investor Events
In September, embecta will participate in the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain direct
The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products
Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadersh
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
NEW YORK--(BUSINESS WIRE)---- $EMBC #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) and remi